Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist
Neurocrine Biosciences (Nasdaq: NBIX) said it has started a Phase 1 first-in-human study of NBIP-'1968, an investigational GLP-1/GIP/glucagon triple agonist for obesity. The trial will assess single ascending doses for safety and tolerability in adults across BMI categories, with once-weekly subcutaneous dosing. NBIP-'1968 is planned as a fixed-dose combination with NBIP-'2118.
How this was made
The 30-second read
Why it matters
The company advances a once-weekly triple agonist into human testing, which can improve perceived probability of technical success and strengthen the obesity pipeline narrative.
Market read
Traders may reprice NBIX on pipeline momentum as the obesity program moves from preclinical/earlier stages into first-in-human dosing.
What to watch
Key near-term drivers are trial design details (dose levels, stopping rules), tolerability signals for multi-agonists, and whether the fixed-dose combination strategy with NBIP-'2118 is supported by emerging data.
Background
Neurocrine is building an obesity portfolio that includes NBIP-'2118 (Phase 1) and now NBIP-'1968 (new Phase 1 first-in-human).
Ticker impact
Neurocrine initiated a Phase 1 first-in-human study of NBIP-'1968, a once-weekly GLP-1/GIP/glucagon triple agonist for obesity.
Likely modest positive bias for NBIX on the headline, with follow-through dependent on future Phase 1 readouts and any dosing/safety updates.
The release discloses a new clinical start (fresh catalyst) and adds program structure (once-weekly, triple agonist, planned fixed-dose combination with NBIP-'2118), but provides no trial results, endpoints, or guidance.
Market effects
Reinforces ongoing competitive intensity in GLP-1/GIP and multi-agonist obesity development, potentially supporting sentiment across obesity-focused biopharma.
Primarily US biotech sentiment; limited direct regional spillover beyond clinical-stage obesity peers.
Obesity drug development remains globally relevant, but this is an early Phase 1 start with no cross-market regulatory or efficacy signal yet.
Counterpoint
A Phase 1 initiation can be largely procedural; without early safety signals or dose-escalation outcomes, the market may fade the initial enthusiasm.
Key entities
- companyNeurocrine Biosciences, Inc.
Initiated a Phase 1 first-in-human study for NBIP-'1968 in obesity.
- drug_candidateNBIP-'1968
Investigational GLP-1/GIP/glucagon receptor triple agonist intended for once-weekly subcutaneous dosing.
- drug_candidateNBIP-'2118
Investigational corticotropin-releasing factor type 2 receptor agonist currently in Phase 1, intended for fixed-dose combination with NBIP-'1968.
